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AT CDTT Stenting
Femoral vein 60% 100% 2/26
External iliac vein 60% 100% 6/26
Common iliac vein 50% 80% 8/26
IVC 25% 60% -
Follow up: Mean e 1 year (8monthse 19months); Recurrence of
DVT e 2/26; PTS e 0/26 and Pulmonary Embolism e 0/26.
Conclusion: Interventional approach for acute DVT is successful,
promising and feasible. Rapid removal and lysis results in pre-
serving venous valve functions and reducing the incidence of PTS.
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Background: Bone marrow derived stem cells, endothelial pro-
genitor cells (EPCs), protect against atherosclerotic vascular
damage. However, EPCs are depleted in RA and contribute to the
enhanced cardiovascular (CV) risk. Therapeutic potential of aug-
menting EPCs to treat the heightened CV risk of RA has not yet
been exploited. We aimed to investigate the effect of rosuvastatin
on EPCs population, endothelial dysfunction, nitrite, adhesion
molecules and on markers of inflammation in RA.
Methods: 50 RA patients, randomized to receive 24 weeks of
treatment with rosuvastatin (10mg/day, n¼25) or placebo (n¼25)
as an adjunct to existing stable antirheumatic drugs. EPCs (CD34+/
CD133+) were quantified by Flow Cytometry. Flow mediated
dilatation (FMD) was assessed by AngiodefenderTM (Everest
Genomic Ann Arbor, United States). Inflammatory measures
included DAS28, CRP, ESR, Pro-inflammatory cytokines (TNF-a, IL-
6 and IL-1), levels of serum nitrite, lipids and adhesion molecules
(ICAM-1 and VCAM-1) was done at baseline and after treatment.
Results: At baseline, inflammatory measures, pro-inflammatory
cytokines, adhesion molecules and nitrite levels were elevated
and EPCs and endothelial function were impaired among both
groups. At 24 wks: DAS28, ESR, CRP, TNF-a, IL-6, nitrite and ICAM-
1 improved significantly in rosuvastatin group. EPCs increased
significantly after treatment with rosuvastatin as compared with
placebo. FMD improved significantly in the rosuvastatin group.
Rosuvastatin exerted positive effect on lipids. Significant inverse
correlation observed between EPCs and CRP, TNF-a, ICAM-1and
FMD after rosuvastatin treatment.
Conclusion: First study to show that rosuvastatin augments EPCs
population in RA mediated by lowering the cytokine levels, which
downregulates adhesion molecule, CRP and nitric oxide produc-
tion. This defines a novel mechanism of rosuvastatin treatment in
RA: the augmentation of EPCs with improvement in inflammatory
disease activity and endothelial dysfunction.
New oral anticoagulants in atrial fibrillation
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Background: Atrial fibrillation (AF) is a common arrhythmia, and
is an important cause of stroke. Risk of stroke and bleeding need
to be assessed before initiating anticoagulant treatment. New oral
anticoagulants (NOACs) are available now as an alternative to
vitamin K antagonists (VKA).
Objective: Our objective was to study the incidence of valvar AF
versus nonvalvar AF, the scores for risk of stroke and bleeding and
the use of NOACs in a tertiary case hospital.
Methods: Cases of atrial fibrillation hospitalized or seen in out
patient over a period of two years were studied. CHA2DS2VASc
and HASBLED scores were applied to all cases of nonvalvar AF.
Creatinine clearance was calculated by Cockroft formula.
Results: There were 60 patients of AF, 30 being male. Mean age
was 66.6 years overall, 62.6 years for male and 70.6 for female
patients. 43 (71.6 %) patients had nonvalvar AF and 17 (28 .4 %) had
valvar AF. OF 17 cases of valvular AF, 04 had prosthetic valve and
all were on VKA.
For the 43 patients of nonvalvar AF, the mean CHA2DS2VASc
score was 2.8 and the mean HASBLED score was 1.5. Fifteen pa-
tients received dabigatran. Of these 15 patents, one shifted from
VKA to dabigatran as she found frequent INR monitoring incon-
venient. 35 opted for VKA for economic reasons and 5 declined to
have any anticoagulation. In one patient, oral anticoagulation was
not started since he had subdural hematoma. In four patients, oral
anticoagulation was not indicated as the CHA2DS2VASc score was
0. Amongst 15 patients who received dabigatran, 11 were on 110
mg twice a day dose because of age, renal dysfunction and body
weight, 4 were on 150 mg twice a day. All these patients tolerated
dabigatran well.
Conclusion: There were more nonvalvar AF cases than valvar AF
and female patients were older. CHA2DS2VASc and HASBLED
scores are easy to apply and help in decision making on initiation
of oral anticoagulants in nonvalvar AF patients. Dabigatran is an
attractive alternative to VKA to prevent stroke in nonvalvar AF.
Cost, compliance, comorbidites and coadministration of other
drugs may be constraints for the use of NOACs.
To study Troponin T levels and its significance in
relation to mortality and morbidity in acute
ischemic stroke
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Background: Troponin T levels have been shown to have a very
good correlation with cardiac stroke or myocardial infarction. In
this study Troponin T levels were evaluated in patients of acute
ischemic stroke.
It follows that Troponin T levels must have a correlation with
morbidity and mortality in these patients (pt.).
Methods: Pt of acute ischemic stroke confirmed by CT scan or MRI
within 72 hr of stroke onset, admitted in medicine ward of L.L.R
and associated hospital in G.S.V.M medical college Kanpur and
measurement of cTn T between 12-72 hr of stroke onset. There
were 45 patients in study who were admitted over a period of
January 2010 to September 2011.
Results: 17.8% of patients in study show rise in troponin T
(>0.01mcgm/dl) out of which 37.5% pt had poor outcome while
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